rs117613935 - RN7SL292P - SGO1P2
Magnitude 2.8 · 1 study on file
Reported associations
-
Genome-wide association studies of antidepressant class response and treatment-resistant depression - Unknown journal (n.d.) · Unknown authors · PubMed 33106475
ABSTRACT: The "antidepressant efficacy" survey (AES) was deployed to > 50,000 23andMe, Inc. research participants to investigate the genetic basis of treatment-resistant depression (TRD) and non-treatment-resistant depression (NTRD). Genome-wide association studies (GWAS) were performed, including TRD vs. NTRD, selective serotonin reuptake inhibitor (SSRI) responders vs. non-responders, serotonin-norepinephrine reuptake inhibitor (SNRI) responders vs. non-responders, and norepinephrine-dopamine reuptake inhibitor responders vs. non-responders. Only the SSRI association reached the genome-wide significance threshold (p < 5 × 10−8): one genomic region in RNF219-AS1 (SNP rs4884091, p = 2.42 × 10−8, OR = 1.21); this association was also observed in the meta-an
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
antidepressant response variant in medication selection Moderate
This variant is associated with altered antidepressant medication response and increased treatment resistance risk in depression
Discuss with psychiatrist or prescribing physician if considering antidepressant therapy